Phillip Kantharidis

75 Commercial Road
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease.

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease.

Journal: Diabetes

Published: October 26, 2025

Proximal tubular deletion of superoxide dismutase-2 reveals disparate effects on kidney function in diabetes.

Proximal tubular deletion of superoxide dismutase-2 reveals disparate effects on kidney function in diabetes.

Journal: Redox biology

Published: December 18, 2024

Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction.

Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction.

Journal: Cardiovascular diabetology

Published: August 09, 2024

miR-214 and Its Primary Transcript Dnm3os Regulate Fibrosis and Inflammation Through RAGE Signaling in Diabetic Kidney Disease.

miR-214 and Its Primary Transcript Dnm3os Regulate Fibrosis and Inflammation Through RAGE Signaling in Diabetic Kidney Disease.

Journal: Diabetes

Published: February 12, 2024

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease.

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease.

Journal: International journal of molecular sciences

Published: November 18, 2023

YB-1: the Jekyll and Hyde of kidney disease?

YB-1: the Jekyll and Hyde of kidney disease?

Journal: Kidney international

Published: September 20, 2023

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase.

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase.

Journal: Frontiers in cardiovascular medicine

Published: May 10, 2023

Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.

Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.

Journal: Kidney international

Published: February 15, 2023

Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A4 Mimetics (QNX-sLXms).

Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A4 Mimetics (QNX-sLXms).

Journal: Journal of medicinal chemistry

Published: June 17, 2021

Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.

Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.

Journal: Nature reviews. Nephrology

Published: June 16, 2021

Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development.

Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 09, 2020

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs.

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs.

Journal: Frontiers in pharmacology

Published: July 27, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026